Rescheduling Hydrocodone Combination Products: Lessons from New York State

Published Online: Friday, January 24, 2014
Follow Pharmacy_Times:
In this video, Jeff Fudin, PharmD, FCCP, adjunct associate professor at the Albany College of Pharmacy and adjunct assistant professor at the UCONN School of Pharmacy, discusses the effect of rescheduling hydrocodone combination products as CII in New York State on prescription of other opioids, including oxycodone.
 
This is the eighth in a series of videos in which Dr. Fudin argues against categorizing hydrocodone combination products as Schedule II drugs, and Mary Lynn McPherson, PharmD, argues in favor of doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Drug addiction is one thing, but diverting that poison onto the streets when pharmacists are told in no uncertain terms not to do so isn’t looked upon so forgivingly.
While extended-release opioid analgesics are an essential component of pain management, abuse and misuse of these medications can cause substantial morbidity and mortality.
The rate of deaths from opiate medications in the United States has increased 4-fold over the past decade.
Leading health care organizations have endorsed new bipartisan legislation intended to help reduce prescription drug abuse.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$